1 – 20 of 37
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
High use of pain, depression, and anxiety drugs in hemophilia : more than 3000 people with hemophilia in an 11-year Nordic registry study
(
- Contribution to journal › Article
-
Mark
Report on 4 cases with decreased recovery due to neutralizing antibodies specific for PEGylated recombinant factor VIII
(
- Contribution to journal › Article
- 2022
-
Mark
Factor IX antibodies and tolerance in hemophilia B in the Nordic countries - The impact of F9 variants and complications
(
- Contribution to journal › Article
-
Mark
Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children : A critical review from the physician's perspective
(
- Contribution to journal › Scientific review
- 2020
-
Mark
Direct comparison of two extended half-life PEGylated recombinant FVIII products : a randomized, crossover pharmacokinetic study in patients with severe hemophilia A
(
- Contribution to journal › Article
- 2019
-
Mark
Direct comparison of two extended-half-life recombinant FVIII products : a randomized, crossover pharmacokinetic study in patients with severe hemophilia A
(
- Contribution to journal › Article
- 2017
-
Mark
Comparative burden of arthropathy in mild haemophilia : a register-based study in Sweden
(
- Contribution to journal › Article
-
Mark
Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients : Results of the INSIGHT case-control study
(
- Contribution to journal › Article
-
Mark
Effect of late prophylaxis in hemophilia on joint status : A randomized trial
(
- Contribution to journal › Article
- 2016
-
Mark
Does the intensity and quality of treatment and not only the factor VIII level influence global hemostasis in patients with hemophilia A?
(
- Contribution to journal › Letter
-
Mark
Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products
(
- Contribution to journal › Article
-
Mark
Aspects of prophylactic treatment of hemophilia
(
- Contribution to journal › Scientific review
- 2014
-
Mark
The Fc gamma receptor IIa R131H polymorphism is associated with inhibitor development in severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Factor VIII therapy for hemophilia A: current and future issues
(
- Contribution to journal › Scientific review
- 2013
-
Mark
Exploring Anti-FVIII Antibodies in Haemophilia A - Role in In Vitro Haemostasis and Clinical Disease
(
- Thesis › Doctoral thesis (compilation)
- 2012
-
Mark
Origin of Swedish hemophilia A mutations
(
- Contribution to journal › Article
-
Mark
Optimizing joint function : new knowledge and novel tools and treatments
(
- Contribution to journal › Article
- 2009
-
Mark
Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A
(
- Contribution to journal › Article
- 2001
-
Mark
Somatic mosaicism in hemophilia A: A fairly common event
(
- Contribution to journal › Article